Altered EEG Theta Activity Characterizes Parkinson’s disease with Levodopa-induced Dyskinesia
Objective: We explored the relationship between the build-up and the downscaling process in patients with Parkinson’s disease by analyzing theta frequency spectral bands. Background: During…Impact of IPX203 on Parkinson’s patients’ motor states upon awakening: analysis of patient diary data
Objective: To evaluate “On” upon awakening in Parkinson’s disease patients taking IPX203 in the RISE-PD phase 3 clinical trial. Background: IPX203 is a novel extended-release,…A Preliminary Report on the Clinical Profile of People with PD at an Outpatient Clinic in Malawi
Objective: The objective of the study is to analyze the clinical and socio-demographic characteristics of people with Parkinson`s (PwP) attending the adult neurology outpatient clinic…Genetic Variants and Levodopa Response in Parkinson’s Disease: Insights from MAO-B and DAT1 Polymorphisms
Objective: This study aimed to find the association of genetic variations between Parkinson’s disease (PD) patients with and without levodopa-induced dyskinesia (LID). we intended to…24 Hour Maxillofacial Administration of Levodopa in a Parkinsons Patient -An Alternative Route of Administration in Parkinsons Disease
Objective: To assess tolerability, feasibility, safety and to assess outcome measures clinically as well as by serum levels over 24 hours, using the alternative maxillofacial…Efficacy and Safety of Controlled-Release Levodopa in Parkinson’s Disease: a Systematic Review and Meta-Analysis
Objective: To evaluate the efficacy and safety of controlled-release levodopa (CRLD) compared with standard release levodopa (SRLD) in patients with Parkinson’s Disease (PD) and motor…Free-Viewing Eye Tracking and the Effect of Levodopa in Parkinson’s Disease
Objective: The objective of our study is to determine whether differences in oculomotor function and blink rate correlate to the off-and on- medication state in a cohort of…Long-Term Safety and Efficacy of Foscarbidopa/Foslevodopa in Patients with Advanced Parkinson’s Disease: Results From an Ongoing Phase 3 Open-Label Extension with Up to 1 Year Follow-Up
Objective: Evaluate long-term safety and efficacy of foslevodopa/foscarbidopa (LDp/CDp) among people with advanced Parkinson’s disease (aPD). Background: As aPD progresses, erratic gastric emptying and pulsatile…Real-World Multicenter Analysis of Levodopa Equivalent Daily Dosage Algorithms- Capturing Geographical and Demographic Disparities in Parkinson’s Disease Therapy Spanning Six Countries and Two Continents
Objective: To assess the influence of updated Levodopa Equivalent Daily Dosage (LEDD) conversion factors in capturing the newer therapies in Parkinson’s Disease (PD) and therapy…Preventing Medication Errors for Hospitalized People with Parkinson’s Disease – Results of Six Months of Proactive Intervention
Objective: To determine whether a Parkinson’s disease (PD) Inpatient Program will prevent medication errors and ultimately improve the safety and quality of care for hospitalized…
- « Previous Page
- 1
- 2
- 3
- 4
- 5
- …
- 57
- Next Page »